In a poster presentation at the 2016 ASCO Annual Meeting in Chicago, MorphoSys presented updated safety and efficacy data from an ongoing open-label, multicenter, Phase 1/2a clinical trial investigating MOR202 monotherapy in combination with lenalidomide (Len) and pomalidomide (Pom) plus dexamethasone (Dex) in 63 patients with relapsed/refractory multiple myeloma…
The Moffitt Cancer Center has completed a Phase 1 clinical trial of selinexor combined with liposomal doxorubicin and dexamethasone for the treatment of relapsed and refractory multiple myeloma (MM) patients. The results of the trial were presented June 6 in Chicago at the 2016 Annual Meeting of the…
The European Commission (EC) has granted provisional approval to Janssen’s Darzalex (daratumumab) as a monotherapy for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are double refractory to a…
An immune-based vaccine created by researchers at Buffalo, New York’s Roswell Park Cancer Institute (RPCI) is now moving to its third study. The new clinical trial will evaluate whether SurVaxM — a cancer vaccine that promotes immune response to the survivin molecule, a critical protein believed to maintain…
Iceni Pharmaceuticals, formerly known as Big DNA Ltd., announced plans to soon begin testing its lead product Cilcane (cilengitide) as a first-in-class treatment for multiple myeloma (MM). The company, working with Merck Serono, was previously evaluating cilengitide in late-stage clinical trials as a potential treatment for glioblastoma, a brain cancer. Cilengitide is…
The International Myeloma Foundation (IMF), the largest organization focusing specifically on multiple myeloma (MM), is now alerting that a reportedly flawed document evaluating the cost of myeloma drugs can dangerously oversimplify a complex issue, limiting patients’ access to the best possible treatments. According to IMF, the report controversially concludes…
Positive data for the Phase 1 trial of PharmaMar’s plitidepsin combined with bortezomib and dexamethasone for the treatment of relapsed and/or refractory multiple myeloma will be presented at the 52nd Congress of the American Society of the Clinical Oncology (ASCO) June 3-7  in Chicago. Dr. MarÃa Victoria Mateos, M.D., of the Hematological…
Amgen announced it will present new data on its cancer portfolio at the 21st Congress of the European Hematology (EHA) Association taking place next month in Copenhagen. The data will include recent evaluations of the drugs Blincyto (blinatumomab), Kyprolis (carfilzomib), Aranesp (darbepoetin alfa) and Nplate (romiplostim) in treating a range of malignancies, such as multiple…
Spain-based PharmaMar announced the company will present data from several clinical studies of three of its anti-tumoral compounds of marine origin — plitidepsin, Yondelis (trabectedin), and PM1183 — at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting June 3-7 in Chicago. “The results that we are going to…
Results from an ongoing clinical trial supports the use of upfront autologous stem cell transplantation (ASCT) to treat multiple myeloma patients age 65 or younger. The findings, in a report titled “Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of…
Get regular updates to your inbox.